Clinical Trial Datasets
ACTG 302 clinical trial
Shulman, NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA. Subtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients. JAIDS. 2002 Oct 1;31(2):121-7.
Katzenstein, DA, Hughes MD, Albrecht M, Liou SH, Murphy R, Balfour H, Para M, Hammer S. AIDS Clinical Trials Group 302 Study Team. Virologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment of Human Immunodeficiency Virus Infection. AIDS Res Hum Retroviruses. 2001 Feb 10;17(3):203-10.
Katzenstein, DA, Hughes MD, Albrecht M, Hammer S, Para M, Murphy R, Valdez H, Haubrich R, Liou S,. AIDS Clinical Trials Group 302 Study Team. Virologic and CD4+ Cell Responses to New Nucleoside Regimens: Switching to Stavudine or Adding Lamivudine after Prolonged Zidovudine Treatment of Human Immunodeficiency Virus Infection. AIDS Res Hum Retroviruses. 2000 Jul 20;16(11)1031-7.
Nucleotide sequences in fasta format
Composite alignment (of sequences at baseline)
List of sequences with stop codon, ambiguity codon and unusual residues
Method: Direct PCR, Dideoxy terminator sequencing
Integrated view of ARV, genotypes, RNA and CD4 on 80 patients
The Microsoft Access database ACTG302Summary.mdb was created on 356 patients for whom sequences and ARV histories are available and contains tables with treatment, mutations, RNA levels and CD4 counts.
The files contained ACTG302Summary.mdb (the description of each file)